BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dwyer JB, Stringaris A, Brent DA, Bloch MH. Annual Research Review: Defining and treating pediatric treatment-resistant depression. J Child Psychol Psychiatry 2020;61:312-32. [PMID: 32020643 DOI: 10.1111/jcpp.13202] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Otter M, Kothgassner OD, Lepuschütz L, Drahos S, Plener PL. The impact of the CoVid-19 pandemic on rates of adolescents receiving psychopharmacological medication in Austria.. [DOI: 10.21203/rs.3.rs-2666963/v1] [Reference Citation Analysis]
2 Karl S, Methfessel I, Weirich S, Rothermel B, Crozier J, Besse M, Reinhardt M, Buchmann J, Dück A, Schulz J, Zilles-Wegner D, Häßler F, Kölch M, Uebel von Sandersleben H, Poustka L, Sartorius A. Electroconvulsive Therapy in Children and Adolescents in Germany-A Case Series From 3 University Hospitals. J ECT 2022;38:249-54. [PMID: 35700967 DOI: 10.1097/YCT.0000000000000861] [Reference Citation Analysis]
3 Pettitt RM, Brown EA, Delashmitt JC, Pizzo MN. The Management of Anxiety and Depression in Pediatrics. Cureus 2022. [DOI: 10.7759/cureus.30231] [Reference Citation Analysis]
4 Wallman EJ, Segrave RA, Gordon MS, Fraser MJOB, Pavlou C, Melvin GA. Acceptability, safety and tolerability of antidepressant repetitive transcranial magnetic stimulation for adolescents: A mixed-methods investigation. J Affect Disord 2022;310:43-51. [PMID: 35429525 DOI: 10.1016/j.jad.2022.04.057] [Reference Citation Analysis]
5 Mortazavi R, Lalouni M, Grudin R, Serlachius E, Sundberg CJ, Norrbom J, Larsson I, Haglund E, Ivarsson A, Lenhard F, Cronqvist T, Ingemarsson K, Mårsell Å, Rask O, Jarbin H. Moderate-to-vigorous group aerobic exercise versus group leisure activities for mild-to-moderate depression in adolescents: study protocol for a multicentre randomised controlled trial. BMJ Open 2022;12:e060159. [PMID: 35820753 DOI: 10.1136/bmjopen-2021-060159] [Reference Citation Analysis]
6 Dwyer JB, Landeros-weisenberger A, Johnson JA, Londono Tobon A, Flores JM, Nasir M, Couloures K, Sanacora G, Bloch MH. Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial. FOC 2022;20:241-251. [DOI: 10.1176/appi.focus.22020004] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Rice SM, McKechnie B, Cotton S, Brooker A, Pilkington V, Youzchalveen B, Schmaal L, Davey CG. Severe and complex youth depression: Clinical and historical features of young people attending a tertiary mood disorders clinic. Early Interv Psychiatry 2022;16:316-22. [PMID: 34173340 DOI: 10.1111/eip.13183] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
8 Seewoo BJ, Rodger J, Demitrack MA, Heart KL, Port JD, Strawn JR, Croarkin PE. Neurostructural Differences in Adolescents With Treatment-Resistant Depression and Treatment Effects of Transcranial Magnetic Stimulation. Int J Neuropsychopharmacol 2022;25:619-30. [PMID: 35089358 DOI: 10.1093/ijnp/pyac007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
9 Dopp R, Reddy P, Hanna G. Child with Alterations of Mood. Symptom-Based Approach to Pediatric Neurology 2022. [DOI: 10.1007/978-3-031-10494-7_6] [Reference Citation Analysis]
10 Children and Adolescents. The Maudsley Prescribing Guidelines in Psychiatry 2021. [DOI: 10.1002/9781119870203.mpg005] [Reference Citation Analysis]
11 Courtney DB, Watson P, Chan BW, Bennett K, Krause KR, Offringa M, Butcher NJ, Monga S, Neprily K, Zentner T, Rodak T, Szatmari P. Forks in the road: Definitions of response, remission, recovery, and other dichotomized outcomes in randomized controlled trials for adolescent depression. A scoping review. Depress Anxiety 2021;38:1152-68. [PMID: 34312952 DOI: 10.1002/da.23200] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
12 Hazell P. Updates in treatment of depression in children and adolescents. Curr Opin Psychiatry 2021;34:593-9. [PMID: 34456305 DOI: 10.1097/YCO.0000000000000749] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
13 Strawn JR, Poweleit EA, Uppugunduri CRS, Ramsey LB. Pediatric Therapeutic Drug Monitoring for Selective Serotonin Reuptake Inhibitors. Front Pharmacol 2021;12:749692. [PMID: 34658889 DOI: 10.3389/fphar.2021.749692] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
14 Campisi SC, Krause KR, Chan BWC, Courtney DB, Bennett K, Korczak DJ, Szatmari P. Eating, sleeping and moving recommendations in clinical practice guidelines for paediatric depression: umbrella review. BJPsych Open 2021;7:e185. [PMID: 34607616 DOI: 10.1192/bjo.2021.1020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Mathai DS, McCathern AG, Guzick AG, Schneider SC, Weinzimmer SA, Cepeda SL, Garcia-Romeu A, Storch EA. Parental Attitudes Toward Use of Ketamine in Adolescent Mood Disorders and Suicidality. J Child Adolesc Psychopharmacol 2021;31:553-61. [PMID: 34665021 DOI: 10.1089/cap.2021.0078] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
16 Benarous X, Cravero C, Jakubowicz B, Morales P, Cohen D. Looking for the Good Timing: Predictors of Length of Stay and Therapeutic Outcomes in Adolescent Inpatients with Severe or Treatment-Refractory Mood Disorders. J Child Adolesc Psychopharmacol 2021;31:268-78. [PMID: 33909453 DOI: 10.1089/cap.2020.0138] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
17 Carboni E, Carta AR, Carboni E, Novelli A. Repurposing Ketamine in Depression and Related Disorders: Can This Enigmatic Drug Achieve Success? Front Neurosci 2021;15:657714. [PMID: 33994933 DOI: 10.3389/fnins.2021.657714] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
18 Oberman LM, Hynd M, Nielson DM, Towbin KE, Lisanby SH, Stringaris A. Repetitive Transcranial Magnetic Stimulation for Adolescent Major Depressive Disorder: A Focus on Neurodevelopment. Front Psychiatry 2021;12:642847. [PMID: 33927653 DOI: 10.3389/fpsyt.2021.642847] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
19 Vankawala J, Naples G, Avila-Quintero VJ, Ramírez KL, Flores JM, Bloch MH, Dwyer JB. Meta-Analysis: Hemodynamic Responses to Sub-anesthetic Doses of Ketamine in Patients With Psychiatric Disorders. Front Psychiatry 2021;12:549080. [PMID: 33841195 DOI: 10.3389/fpsyt.2021.549080] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
20 Croarkin PE, Elmaadawi AZ, Aaronson ST, Schrodt GR Jr, Holbert RC, Verdoliva S, Heart KL, Demitrack MA, Strawn JR. Left prefrontal transcranial magnetic stimulation for treatment-resistant depression in adolescents: a double-blind, randomized, sham-controlled trial. Neuropsychopharmacology 2021;46:462-9. [PMID: 32919400 DOI: 10.1038/s41386-020-00829-y] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 8.5] [Reference Citation Analysis]
21 Strawn JR, Croarkin PE. Commentary: Treatment failure and success: a commentary on defining and treating pediatric treatment-resistant depression - reflections on Dwyer et al. (2020). J Child Psychol Psychiatry 2020;61:333-5. [PMID: 32034765 DOI: 10.1111/jcpp.13207] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]